First Header Logo Second Header Logo

Connection

Karen Haas to Adjuvants, Immunologic

This is a "connection" page, showing publications Karen Haas has written about Adjuvants, Immunologic.
Connection Strength

1.296
  1. Phipps JP, Haas KM. An Adjuvant That Increases Protective Antibody Responses to Polysaccharide Antigens and Enables Recall Responses. J Infect Dis. 2019 01 07; 219(2):323-334.
    View in: PubMed
    Score: 0.634
  2. Haas KM, Toapanta FR, Oliver JA, Poe JC, Weis JH, Karp DR, Bower JF, Ross TM, Tedder TF. Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression. J Immunol. 2004 May 15; 172(10):5833-7.
    View in: PubMed
    Score: 0.230
  3. Dyevoich AM, Disher NS, Haro MA, Haas KM. A TLR4-TRIF-dependent signaling pathway is required for protective natural tumor-reactive IgM production by B1 cells. Cancer Immunol Immunother. 2020 Oct; 69(10):2113-2124.
    View in: PubMed
    Score: 0.174
  4. Dyevoich AM, Haas KM. Type I IFN, Ly6C+ cells, and Phagocytes Support Suppression of Peritoneal Carcinomatosis Elicited by a TLR and CLR Agonist Combination. Mol Cancer Ther. 2020 06; 19(6):1232-1242.
    View in: PubMed
    Score: 0.172
  5. Haas KM, Estes DM. The identification and characterization of a ligand for bovine CD5. J Immunol. 2001 Mar 01; 166(5):3158-66.
    View in: PubMed
    Score: 0.046
  6. Poe JC, Haas KM, Uchida J, Lee Y, Fujimoto M, Tedder TF. Severely impaired B lymphocyte proliferation, survival, and induction of the c-Myc:Cullin 1 ubiquitin ligase pathway resulting from CD22 deficiency on the C57BL/6 genetic background. J Immunol. 2004 Feb 15; 172(4):2100-10.
    View in: PubMed
    Score: 0.014
  7. Austin AS, Haas KM, Naugler SM, Bajer AA, Garcia-Tapia D, Estes DM. Identification and characterization of a novel regulatory factor: IgA-inducing protein. J Immunol. 2003 Aug 01; 171(3):1336-42.
    View in: PubMed
    Score: 0.014
  8. Davis WC, Konzek RL, Haas K, Estes DM, Hamilton MJ, Call DR, Apostolopoulos V, McKenzie IF. Use of the mannan receptor to selectively target vaccine antigens for processing and antigen presentation through the MHC class I and class II pathways. Ann N Y Acad Sci. 2002 Oct; 969:119-25.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.